Mechanism of rebalanced hemostasis in liver cirrhosis and the timing of blood transfusion and anticoagulation

Huan MA; Mei HAN; Yue ZHANG; Chunmeng JIANG; Hui LIU

doi:10.3969/j.issn.1001-5256.2022.09.037

Volume 38 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(9): 2141-2145

PDF( 1954 KB)

Mechanism of rebalanced hemostasis in liver cirrhosis and the timing of blood transfusion and anticoagulation

DOI: 10.3969/j.issn.1001-5256.2022.09.037

Department of Gastroenterology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116000, China

Research funding:

National Natural Science Foundation of China (82100620);

Doctoral Startup Reasearch Fund of Liaoning Province (2021-BS-218);

Dalian Medical Science Research Program Project (2112015)

More Information

Corresponding author: LIU Hui, liuhuidoctor@dmu.edu.cn(ORCID: 0000-0003-4721-560X)
Received Date: 2022-02-14
Accepted Date: 2022-03-20
Published Date: 2022-09-20

Abstract

Abstract

Reconstructed rebalanced hemostasis exists in patients with liver cirrhosis, while such balance is unstable and can be easily broken by stress factors, which may lead to bleeding or thrombosis. There is a lack of effective strategies to prevent and solve the disrupted balance in clinic due to the complex pathogenesis of rebalanced hemostasis, limited testing methods, and insufficient awareness among clinicians. With reference to the articles in recent years, this article summarizes the mechanism of rebalanced hemostasis in liver cirrhosis and the causes of bleeding and thrombosis and discuss the association between blood transfusion and rebalanced hemostasis and the selection of anticoagulant drugs during thrombosis, in order to provide a theoretical basis and new ideas for solving related issues in clinical practice.
- Liver Cirrhosis,
- Hemorrhage,
- Blood Transfusion,
- Anticoagulants

FullText(HTML)

References(45)

References

[1]	TRIPODI A. Hemostasis abnormalities in cirrhosis[J]. Curr Opin Hematol, 2015, 22(5): 406-412. DOI: 10.1097/MOH.0000000000000164.
[2]	LISMAN T, PORTE RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences[J]. Blood, 2010, 116(6): 878-885. DOI: 10.1182/blood-2010-02-261891.
[3]	MCMURRY HS, JOU J, SHATZEL J. The hemostatic and thrombotic complications of liver disease[J]. Eur J Haematol, 2021, 107(4): 383-392. DOI: 10.1111/ejh.13688.
[4]	AREF S, MABED M, SELIM T. Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia[J]. Hematology, 2004, 9(5-6): 351-356. DOI: 10.1080/10245330400010620.
[5]	ZERMATTEN MG, FRAGA M, MORADPOUR D, et al. Hemostatic alterations in patients with cirrhosis: From primary hemostasis to fibrinolysis[J]. Hepatology, 2020, 71(6): 2135-2148. DOI: 10.1002/hep.31201.
[6]	MITCHELL O, FELDMAN DM, DIAKOW M, et al. The pathophysiology of thrombocytopenia in chronic liver disease[J]. Hepat Med, 2016, 8: 39-50. DOI: 10.2147/HMER.S74612.
[7]	KUJOVICH JL. Coagulopathy in liver disease: a balancing act[J]. Hematology Am Soc Hematol Educ Program, 2015, 2015: 243-249. DOI: 10.1182/asheducation-2015.1.243.
[8]	LISMAN T, BONGERS TN, ADELMEIJER J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity[J]. Hepatology, 2006, 44(1): 53-61. DOI: 10.1002/hep.21231.
[9]	DONG JF, MOAKE JL, NOLASCO L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions[J]. Blood, 2002, 100(12): 4033-4039. DOI: 10.1182/blood-2002-05-1401.
[10]	FENG Y, LI X, XIAO J, et al. ADAMTS13: more than a regulator of thrombosis[J]. Int J Hematol, 2016, 104(5): 534-539. DOI: 10.1007/s12185-016-2091-2.
[11]	SINEGRE T, DURON C, LECOMPTE T, et al. Increased factor Ⅷ plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis[J]. J Thromb Haemost, 2018, 16(6): 1132-1140. DOI: 10.1111/jth.14011.
[12]	INTAGLIATA NM, DAVIS J, CALDWELL SH. Coagulation pathways, hemostasis, and thrombosis in liver failure[J]. Semin Respir Crit Care Med, 2018, 39(5): 598-608. DOI: 10.1055/s-0038-1673658.
[13]	TRIPODI A, PRIMIGNANI M, MANNUCCI PM, et al. Changing concepts of cirrhotic coagulopathy[J]. Am J Gastroenterol, 2017, 112(2): 274-281. DOI: 10.1038/ajg.2016.498.
[14]	WU X, YAO Z, ZHAO L, et al. Phosphatidylserine on blood cells and endothelial cells contributes to the hypercoagulable state in cirrhosis[J]. Liver Int, 2016, 36(12): 1800-1810. DOI: 10.1111/liv.13167.
[15]	LIAW PC, ITO T, IBA T, et al. DAMP and DIC: The role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC[J]. Blood Rev, 2016, 30(4): 257-261. DOI: 10.1016/j.blre.2015.12.004.
[16]	CHAPIN JC, HAJJAR KA. Fibrinolysis and the control of blood coagulation[J]. Blood Rev, 2015, 29(1): 17-24. DOI: 10.1016/j.blre.2014.09.003.
[17]	RIJKEN DC, KOCK EL, GUIMARÃES AH, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests[J]. J Thromb Haemost, 2012, 10(10): 2116-2122. DOI: 10.1111/j.1538-7836.2012.04901.x.
[18]	FERRO D, CELESTINI A, VIOLI F. Hyperfibrinolysis in liver disease[J]. Clin Liver Dis, 2009, 13(1): 21-31. DOI: 10.1016/j.cld.2008.09.008.
[19]	PECK-RADOSAVLJEVIC M. Thrombocytopenia in chronic liver disease[J]. Liver Int, 2017, 37(6): 778-793. DOI: 10.1111/liv.13317.
[20]	RODRÍGUEZ-CASTRO KI, ANTONELLO A, FERRARESE A. Spontaneous bleeding or thrombosis in cirrhosis: What should be feared the most?[J]. World J Hepatol, 2015, 7(14): 1818-1827. DOI: 10.4254/wjh.v7.i14.1818.
[21]	TRIPODI A, ANSTEE QM, SOGAARD KK, et al. Hypercoagulability in cirrhosis: causes and consequences[J]. J Thromb Haemost, 2011, 9(9): 1713-1723. DOI: 10.1111/j.1538-7836.2011.04429.x.
[22]	MA SD, WANG J, BEZINOVER D, et al. Inherited thrombophilia and portal vein thrombosis in cirrhosis: A systematic review and meta-analysis[J]. Res Pract Thromb Haemost, 2019, 3(4): 658-667. DOI: 10.1002/rth2.12253.
[23]	ZHAN XL, JI Y, WANG YD. Laparoscopic splenectomy for hypersplenism secondary to liver cirrhosis and portal hypertension[J]. World J Gastroenterol, 2014, 20(19): 5794-5800. DOI: 10.3748/wjg.v20.i19.5794.
[24]	WU Y, LI H, ZHANG T, et al. Splanchnic vein thrombosis in liver cirrhosis after splenectomy or splenic artery embolization: A systematic review and meta-analysis[J]. Adv Ther, 2021, 38(4): 1904-1930. DOI: 10.1007/s12325-021-01652-7.
[25]	HUANG D, TAO M, CAO L, et al. Risk factors and anticoagulation effects of portal vein system thrombosis after laparoscopic splenectomy in patients with or without cirrhosis[J]. Surg Laparosc Endosc Percutan Tech, 2019, 29(6): 498-502. DOI: 10.1097/SLE.0000000000000710.
[26]	STRAVITZ RT. Algorithms for managing coagulation disorders in liver disease[J]. Hepatol Int, 2018, 12(5): 390-401. DOI: 10.1007/s12072-018-9886-6.
[27]	LEBRETON A, SINEGRE T, LECOMPTE T, et al. Thrombin generation and cirrhosis: state of the art and perspectives[J]. Semin Thromb Hemost, 2020, 46(6): 693-703. DOI: 10.1055/s-0040-1715102.
[28]	SCHARF RE. Thrombocytopenia and hemostatic changes in acute and chronic liver disease: pathophysiology, clinical and laboratory features, and management[J]. J Clin Med, 2021, 10(7): 1530. DOI: 10.3390/jcm10071530.
[29]	ROBERTS LN, PATEL RK, ARYA R. Haemostasis and thrombosis in liver disease[J]. Br J Haematol, 2010, 148(4): 507-521. DOI: 10.1111/j.1365-2141.2009.08021.x.
[30]	THAI C, OBEN C, WAGENER G. Coagulation, hemostasis, and transfusion during liver transplantation[J]. Best Pract Res Clin Anaesthesiol, 2020, 34(1): 79-87. DOI: 10.1016/j.bpa.2020.03.002.
[31]	O'SHEA RS, DAVITKOV P, KO CW, et al. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis[J]. Gastroenterology, 2021, 161(5): 1615-1627. e1. DOI: 10.1053/j.gastro.2021.08.015.
[32]	VON MEIJENFELDT FA, VAN DEN BOOM BP, ADELMEIJER J, et al. Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease[J]. J Thromb Haemost, 2021, 19(3): 664-676. DOI: 10.1111/jth.15185.
[33]	LIU P, HUM J, JOU J, et al. Transfusion strategies in patients with cirrhosis[J]. Eur J Haematol, 2020, 104(1): 15-25. DOI: 10.1111/ejh.13342.
[34]	RASSI AB, D'AMICO EA, TRIPODI A, et al. Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation[J]. J Hepatol, 2020, 72(1): 85-94. DOI: 10.1016/j.jhep.2019.09.008.
[35]	DROLZ A, HORVATITS T, ROEDL K, et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis[J]. Hepatology, 2016, 64(2): 556-568. DOI: 10.1002/hep.28628.
[36]	PANT A, KOPEC AK, LUYENDYK JP. Role of the blood coagulation cascade in hepatic fibrosis[J]. Am J Physiol Gastrointest Liver Physiol, 2018, 315(2): G171-G176. DOI: 10.1152/ajpgi.00402.2017.
[37]	FLORES B, TRIVEDI HD, ROBSON SC, et al. Hemostasis, bleeding and thrombosis in liver disease[J]. J Transl Sci, 2017, 3(3): 10.15761/JTS. 1000182. DOI: 10.15761/JTS.1000182.
[38]	WITT DM, CLARK NP, KAATZ S, et al. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism[J]. J Thromb Thrombolysis, 2016, 41(1): 187-205. DOI: 10.1007/s11239-015-1319-y.
[39]	INTAGLIATA NM, HENRY ZH, MAITLAND H, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation[J]. Dig Dis Sci, 2016, 61(6): 1721-1727. DOI: 10.1007/s10620-015-4012-2.
[40]	DE GOTTARDI A, TREBICKA J, KLINGER C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis[J]. Liver Int, 2017, 37(5): 694-699. DOI: 10.1111/liv.13285.
[41]	CHUN HS, CHOE AR, LEE M, et al. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis[J]. Clin Mol Hepatol, 2021, 27(4): 535-552. DOI: 10.3350/cmh.2021.0109.
[42]	LEONARDI F, MARIA N, VILLA E. Anticoagulation in cirrhosis: a new paradigm?[J]. Clin Mol Hepatol, 2017, 23(1): 13-21. DOI: 10.3350/cmh.2016.0110.
[43]	ZHANG N, YAO Y, XUE W, et al. Early prophylactic anticoagulation for portal vein system thrombosis after splenectomy: A systematic review and meta-analysis[J]. Biomed Rep, 2016, 5(4): 483-490. DOI: 10.3892/br.2016.755.
[44]	KAWANAKA H, AKAHOSHI T, KINJO N, et al. Impact of antithrombin Ⅲ concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism[J]. Ann Surg, 2010, 251(1): 76-83. DOI: 10.1097/SLA.0b013e3181bdf8ad.
[45]	GONG C, QIN X, YANG J, et al. The best anticoagulation strategy for cirrhotic patients who underwent splenectomy: A network meta-analysis[J]. Gastroenterol Res Pract, 2017, 2017: 9216172. DOI: 10.1155/2017/9216172.

Relative Articles

[1]	Huimin LI, Yizhuo CHEN, Rui ZHAO, Xiao HUANG, Fei HUANG, Huanhuan LI. A comparative analysis of the hemogram and myelogram of patients with liver cirrhosis and the advantages and disadvantages of splenectomy[J]. Journal of Clinical Hepatology, 2023, 39(9): 2217-2224. doi: 10.3969/j.issn.1001-5256.2023.09.028
[2]	Yitong BAI, Lianjie LIN, Dongmei PEI. Value of red blood cell distribution width-to-platelet ratio in evaluating metabolic-associated fatty liver disease and liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(4): 805-809. doi: 10.3969/j.issn.1001-5256.2022.04.013
[3]	Mou SiYu, Yang Zhe, Wu LiQun, Qiu Xuan, Guo JiaMing. Predictive factors for portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(1): 106-111. doi: 10.3969/j.issn.1001-5256.2018.01.022
[4]	Ao Fei, Chen WeiQing. Research advances in portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2018, 34(3): 631-634. doi: 10.3969/j.issn.1001-5256.2018.03.043
[5]	Bao WenChun, Qi XingShun, Tang ShanHong, Li HongYu. An excerpt of the Japanese research group on IPH: diagnosis and treatment guidelines for aberrant portal hemodynamics (2017)[J]. Journal of Clinical Hepatology, 2017, 33(3): 432-434. doi: 10.3969/j.issn.1001-5256.2017.03.006
[6]	Liu ShuYan. Association between cerebral hemodynamic changes and neonatal hyperbilirubinemia[J]. Journal of Clinical Hepatology, 2017, 33(10): 1974-1976. doi: 10.3969/j.issn.1001-5256.2017.10.025
[7]	Tang HanQiu. Clinical effect of laparoscopic splenectomy combined with esophagogastric devascularization in treatment of liver cirrhosis with portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(9): 1743-1746. doi: 10.3969/j.issn.1001-5256.2016.09.022
[8]	Liang XiaoHua, Zhang Feng, Zhu GeYuZheng. Effect of transjugular intrahepatic portosystemic shunt combined with splenic artery embolization on hepatic hemodynamics and liver function in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2112-2117. doi: 10.3969/j.issn.1001-5256.2016.11.021
[9]	Bao HanKang, Wei XiuLi. Clinical effects of hand-assisted laparoscopic vs open splenectomy combined with pericardial devascularization the treatment of portal hypertension in liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 431-433. doi: 10.3969/j.issn.1001-5256.2015.03.027
[10]	Yang ZhengMao, Zhang LingYi. Risk factors for portal vein thrombosis following splenectomy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(7): 1173-1175. doi: 10.3969/j.issn.1001-5256.2015.07.044
[11]	Duan LiWei, Sun Han, Chen YongSheng, Tian YueLi, Li DongFu. Hemodynamic effects of partial splenic artery embolization in patients with liver cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2013, 29(2): 142-145.
[12]	Shang JianZhong, Ma LongFei, Ma HongWei, Zhao QiuFang, Zhao LinHua, Li XiaoFei, Fan YanFeng, Zhang SuE. Effect of autologous bone marrow- derived mesenchymal stem cells on portal hemodynamics in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(11): 848-851. doi: 10.3969/j.issn.1001-5256.2013.10.012
[14]	Jin HongHui, Ding XiaoHong. ROC curve analysis of blood platelet and hyaluronic acid levels for diagnosing cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(6): 456-458.
[15]	Gao Lei, Jing Xiang, Zhao XinMin, Zuo YanLing. Hemodynamics of portal vein in cirrhotic patients with esophageal varices[J]. Journal of Clinical Hepatology, 2010, 26(3): 297-299+305.
[16]	Liu SuLi, Feng ZhiJie, Lu: YanChun, Niu FaLiang. The clinical study of Rhizoma alismatis on hemodynamics of liver cirrohosis and portal hypertension[J]. Journal of Clinical Hepatology, 2006, 22(2): 119-120.
[17]	Qin YouJuan. Correlative study between hemodynamics of portal vein system and Child-Pugh in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2004, 20(1): 21-22.
[18]	Wang ZhiHua, Cai HanZhi, Zhao AnXin, Li XiLing, Yang HongXin. The effects of disconnection and shunt procedure on hepatic hemodynamics and function of active cirrhotic patients with portal hypertension[J]. Journal of Clinical Hepatology, 2002, 18(5): 309-310.
[19]	Dong JiLiang, Sun Jie, Ding XiuHe. Clinical observation of the effects of partial splenic embobization (PSE) on hemodynamics in 24 patients of liver cirrhosis with portal hypertention (LCPH)[J]. Journal of Clinical Hepatology, 2002, 18(6): 361-362.

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	康志龙，周益民，宋燕州，张昆，苏一男，魏文平，赵新，李志伟. 靶向免疫治疗联合经肝动脉灌注化疗治疗不可切除肝细胞癌的临床效果及转化治疗的影响因素. 中国医学创新. 2025(01): 47-51 .
2.	许海明，胡永奎，梁平，钟腾猛，陆炳站. 中晚期肝癌患者经动脉化疗栓塞治疗后短期效果及长期预后的影响因素分析. 大医生. 2025(06): 27-31 .
3.	彭林辉，陈涛，徐云修修，王捷，陈捷，李永，黄拼搏，钟国平，陈茜，叶聪婷，陈亚进. mFOLFOX7方案全身化疗联合卡瑞利珠单克隆抗体和阿帕替尼治疗肝细胞癌合并Vp4型门静脉癌栓的疗效. 中华消化外科杂志. 2024(02): 265-271 .
4.	李洁，李瑞娟，鲁志兵，曾筱怡. 肝动脉灌注化疗联合程序性死亡受体1抗体及仑伐替尼治疗晚期肝癌合并门静脉癌栓的效果. 中国当代医药. 2024(26): 43-46+51 .
5.	黄乾鑫，神斌，肖晋昌，高志康，吕墩涛，李艳，徐浩，张庆桥. 载药微球经导管动脉化疗栓塞术联合肠系膜上动脉灌注化疗治疗肝细胞癌合并门静脉癌栓的效果分析. 临床肝胆病杂志. 2024(12): 2457-2463 . 本站查看

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (618) PDF downloads(63)

Mechanism of rebalanced hemostasis in liver cirrhosis and the timing of blood transfusion and anticoagulation

DOI: 10.3969/j.issn.1001-5256.2022.09.037